30+
Companies
$2B+
Total Funding
6
Key Markets
Fast
Growth Region

Greater China

Rapidly growing hub with strong government support and AI leadership

First AI Drug in Phase 2

Insilico Medicine

Pharma.AI with Chemistry42 and Biology42. First fully AI-designed drug in Phase 2 (IPF). $400M+ raised.

Hong Kong Series D

Novoheart

MyHeart platform for cardiac organoids. Human heart-in-a-jar technology. CUHK spinout.

Hong Kong Series B

XtalPi

AI for crystal structure prediction and drug formulation. MIT spinout with China operations. $700M+ raised.

Shenzhen Series D

Crown Bioscience

Patient-derived tumor organoids. HuTumorX platform. Global CRO with China operations. JSR owned.

Suzhou JSR Owned

Israel's Innovation Nation

World-leading startup ecosystem with deep tech innovation

Patient-on-Chip + AI

Quris AI

Bio-AI clinical prediction platform. Patient-on-chip integrated with ML for toxicity prediction.

Tel Aviv Series A

Tissue Dynamics

Organ-on-chip for cardiotoxicity. Hebrew University spinout. Cardiac safety testing.

Jerusalem Series A

Accellta

iPSC suspension culture technology. Large-scale pluripotent stem cell production.

Haifa Series A

Japanese Innovation

iPS cell pioneers and advanced manufacturing excellence

CiRA Foundation

CiRA Foundation

Kyoto University iPS cell center. Founded by Nobel laureate Shinya Yamanaka. Clinical-grade iPSC bank.

Kyoto Foundation

Jiksak Bioengineering

Organ-on-chip microfluidic devices. Tokyo-based. Specialized perfusion systems.

Tokyo Private

Fujifilm Cellular Dynamics

iPSC-derived cells. Part of Fujifilm. iCell products for drug discovery.

Osaka Fujifilm

Korean Biotech

Samsung and chaebols driving bio-pharma investment

Samsung Biologics

Major CDMO with cell culture capabilities. World's largest biomanufacturing capacity.

Incheon KRX Listed

MxT Biotech

Organ-on-chip platforms. Seoul-based microfluidics company. Academic spinout.

Seoul Series A

Pacific Innovation

Emerging hubs with strong research infrastructure

Gelomics

GelMA and hydrogel bioinks. Australian materials company. Focus on reproducibility.

Brisbane Series A

Inventia Life Science

RASTRUM bioprinting platform. Australian 3D bioprinting for drug discovery.

Sydney Series A

A*STAR Research

Singapore government research. Biopolis cluster. Organ-on-chip and tissue engineering programs.

Singapore Government

Indian Innovation

Emerging biotech hub with strong pharma manufacturing base

Clinical Trials

Pandorum Technologies

3D bioprinted corneas. First bioprinted cornea implants in clinical trials in India.

Bangalore Clinical

Premas Biotech

Cell culture and biologics. Indian vaccine development. D-Crypt expression platform.

Gurgaon Private

Explore Other Regions

Discover human simulation companies across global biotech hubs

North America Europe All Companies